Bornstein Jonathan 4
4 · Amprius Technologies, Inc. · Filed Mar 7, 2024
Insider Transaction Report
Form 4
Bornstein Jonathan
President of Amprius Lab
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-03-05−109,800→ 1,174,051 totalExercise: $0.05From: 2022-09-14Exp: 2027-03-15→ Common stock (109,800 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-03-06−40,200→ 1,133,851 totalExercise: $0.05From: 2022-09-14Exp: 2027-03-15→ Common stock (40,200 underlying) - Exercise/Conversion
Common stock
2024-03-05$0.05/sh+109,800$5,490→ 109,800 total - Sale
Common stock
2024-03-06$2.78/sh−40,200$111,579→ 0 total - Sale
Common stock
2024-03-05$2.92/sh−109,800$320,462→ 0 total - Exercise/Conversion
Common stock
2024-03-06$0.05/sh+40,200$2,010→ 40,200 total
Footnotes (3)
- [F1]The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.
- [F2]The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.87 to $3, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.